We provide transparent and timely observational evidence for accelerated advancement of healthcare
About us
Sence Research AB is an independent scientific analytical company specialising in epidemiology, pharmacoepidemiology, and outcomes research. Our team brings together epidemiologists, pharmacists, physicians, and health economists — with active academic research embedded in everything we do.
We work at the intersection of rigorous methodology and real-world application: developing and applying the analytical frameworks that turn healthcare data into scientific evidence that informs critical decisions. Our work spans the full evidence lifecycle — from study design, analytical infrastructure and analysis through to publication in peer-reviewed journals.
We are committed to methodological transparency, scientific independence, and continuous improvement.
Our services
Our services are tailored to the needs of each client and engagement. We work across three channels — pharmaceutical companies, healthcare payers, and clinical departments — and at every stage of the evidence lifecycle.
For pharma partners, typical engagements range from early characterisation of target populations and unmet need, through support for TLV and HTA submissions, to post-launch effectiveness programmes and peer-reviewed publication. We design and execute studies end-to-end: protocol development, data access and analytical frameworks creation, analysis, and delivery of publication-ready outputs.
For payers and regional formulary bodies, we provide the evidence infrastructure that makes conditional access credible: pre-specified analyses designed to answer the questions that reimbursement decisions depend on.
For clinical departments, we offer structured kvalitetsuppföljning — rigorous analysis of a department's own patient population benchmarked against guidelines, designed to surface variation and support evidence-based improvement in care.
Our principles
Our mission is to generate rigorous, independent scientific evidence that advances healthcare decisions — for patients, clinicians, payers, and the pharmaceutical industry.
We are certified to ISO/IEC 27001 (Information Security Management), subscribe to the ENCePP Code of Conduct, and follow the ISPE Guidelines for Good Pharmacoepidemiology Practices.
We are actively engaged in the development of methods and analytical frameworks for comparative effectiveness research — publishing not only study results but the methodological boundaries of the approaches we use.
Selected Science
Hypercholesterolemia &
Lipid-Lowering Treatment
Methodological challenges: target trial emulation for PCSK9 inhibitor timing post-MI
To assess whether the clone-censor-weight method can estimate the effectiveness of early vs delayed PCSK9 inhibitor initiation after myocardial infarction.
Early ezetimibe initiation after MI protects against cardiovascular outcomes
To compare cardiovascular outcomes in patients receiving early combination lipid-lowering therapy vs delayed or no ezetimibe after MI.
Nationwide analysis of evolocumab use in Sweden and its effect on LDL-C levels
To describe real-world prescribing patterns of evolocumab and quantify its effect on LDL-C levels in clinical practice.
Our leadership
Thomas Cars, MSc, PhD
Founder & Chief Scientific Officer
Thomas Cars is a pharmacist and holds a PhD in pharmacoepidemiology from Uppsala University. His research is focused on methods and models for comparative effectiveness research mainly using data from electronic health records.
Magnus Göransson, MSc, Stockholm School of Economics
CEO
Magnus Göransson brings over 15 years of leadership experience in diagnostics and medtech, with a focus on commercial strategy, real-world data, and digital transformation. He previously served as General Manager at Roche Diagnostics Sweden and on the board of Swedish Medtech.
Matilda Almstedt, MSc, Pharmacist
COO
Matilda Almstedt brings extensive leadership experience in life sciences and research operations, with a focus on scientific excellence, cross-disciplinary collaboration, and innovation in epidemiological research. She currently serves as Chief Operating Officer at Sence Research, driving scientific and operational excellence and enabling purposeful advancements in collaborative research.
Find us
Smedsgränd 2B,
753 20 Uppsala, Sverige
©2020 by Sence Research AB
Contact
Thomas Cars
MSc, PhD, Founder & Chief Scientific Officer
e-mail:
thomas.cars@sence.com
Matilda Almstedt
MSc, Chief Operating Officer
e-mail:
matilda.almstedt@sence.com
Do you have questions about how we handle data protection?
Contact our external Data Protection Officer.
Anna Rundberg
Data Protection Officer
Secure State Cyber AB
e-mail:
juridik@securestatecyber.com
